Duration of clinical development for antiviral drugs, in total and subdivided into clinical trials and regulatory approval periods, by year of first license and indication in the UK, 1981–2014
| Number | Duration of development (months) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical trials period | Regulatory approval period | Total duration | ||||||||
| Mean | SE | 95% CI | Mean | SE | 95% CI | Mean | SE | 95% CI | ||
| All new drugs | 48 | 64.6 | 4.70 | 55.9 to 73.3 | 12.6 | 0.96 | 10.8 to 14.7 | 77.2 | 4.75 | 68.7 to 86.6 |
| Drugs licensed between | ||||||||||
| 1981–1992 | 7 | 41.7 | 9.90 | 23.5 to 62.6 | 16.3 | 5.02 | 7.3 to 26.8 | 58.0 | 13.2 | 37.6 to 86.4 |
| 1993–2003 | 23 | 63.2 | 5.34 | 53.6 to 73.7 | 11.2 | 1.01 | 9.3 to 13.1 | 74.4 | 5.21 | 64.9 to 84.9 |
| 2004–2014 | 17 | 78.4 | 9.02 | 61.5 to 96.7 | 13.3 | 1.10 | 11.3 to 15.6 | 91.7 | 8.80 | 75.2 to 108.9 |
| Initial licensed indication | ||||||||||
| HIV infection | 26 | 55.8 | 4.18 | 47.5 to 64.1 | 11.8 | 0.94 | 10.0 to 13.5 | 67.6 | 4.43 | 58.7 to 76.5 |
| Hepatitis C infection | 7 | 92.1 | 20.52 | 52.8 to 133.4 | 13.9 | 4.69 | 8.4 to 25.2 | 106.0 | 21.00 | 63.7 to 147.2 |
| Other viral infection | 15 | 66.8 | 7.97 | 51.2 to 83.3 | 13.5 | 1.59 | 10.3 to 16.4 | 80.3 | 7.32 | 66.6 to 95.3 |